Plant Name: Ceriops decandra
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NMUR2; | |
| GPBAR1; ADRA2C; ADRA2A; | |
| PTPN1; PTPN2; CDC25B; | |
| PLA2G1B; TDP1; PKM; HSD17B1; AKR1B10; NOX4; ALOX15; USP2; TNKS; TNKS2; POLB; | |
| ACHE; GAA; | |
| CFTR; | |
| GSK3B; SYK; MAPK1; FLT3; CDK6; CSNK2A1; | |
| CA2; CA12; CA1; CA9; CA14; CA5B; CA5A; CA6; CA7; | |
| AR; | |
| PPARA; PPARD; | |
| ESR1; ESR2; | |
| NR1H4; | |
| KDM4E; | |
| MAOA; PTGS2; XDH; | |
| HIF1A; TP53; NFKB1; | |
| ABCG2; ABCC1; | |
| HTT; LMNA; RAB9A; NPC1; MAPT; THPO; TTR; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.596E-13 | 5.653E-10 | CA1, CA12, CA2, CA5A, CA5B, CA6, CA7, CA9 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.226E-13 | 7.078E-10 | CA2, CA7, CFTR, HIF1A, HTT, MAPK1, NPC1, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.087E-11 | 2.800E-08 | ADRA2A, CA2, CA7, CDK6, CFTR, HIF1A, HTT, MAPK1, NPC1, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.432E-10 | 4.760E-07 | AR, CA1, CA12, CA2, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, NR1H4, PPARA, PPARD, PTPN1, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.662E-09 | 3.089E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.094E-08 | 4.180E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.368E-08 | 4.966E-06 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.920E-08 | 6.333E-06 | AR, CFTR, CYP1A1, CYP1B1, ESR1, FLT3, MAPK1, NFKB1, NOX4, NPC1, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.159E-07 | 4.236E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 3.840E-07 | 6.854E-05 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.805E-07 | 1.547E-04 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, XDH |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.210E-06 | 3.284E-04 | CYP19A1, NFKB1, NR1H4, PPARA, PPARD, PTPN2 |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 2.501E-06 | 3.631E-04 | AR, CDK6, CFTR, ESR1, FLT3, NFKB1, NPC1, NR1H4, PPARD |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 3.224E-06 | 4.500E-04 | ABCC1, ALOX15, PLA2G1B, SYK |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 4.095E-06 | 5.630E-04 | CA2, CA7, CFTR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.095E-06 | 5.630E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 4.506E-06 | 6.020E-04 | AR, ESR1, ESR2, NR1H4, PPARA, PPARD |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 4.762E-06 | 6.284E-04 | ADRA2A, CSNK2A1, CYP1B1, ESR1, GSK3B, MAPT, NFKB1, NR1H4, PPARA, PTGS2, PTPN1, PTPN2, RAB9A, TNKS, TP53 |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 5.039E-06 | 6.610E-04 | AR, CYP1B1, ESR1, ESR2, MAPK1, NFKB1, NR1H4, PLA2G1B, SYK |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 5.617E-06 | 7.280E-04 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 5.617E-06 | 7.280E-04 | GSK3B, HTT, MAPT |
| BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 6.667E-06 | 8.440E-04 | ALOX15, PLA2G1B, PTGS2, SYK |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 8.451E-06 | 1.052E-03 | CDK6, GSK3B, HIF1A, MAPK1, MAPT, PTGS2, PTPN1, PTPN2, SYK, TP53, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.081E-05 | 1.307E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 1.205E-05 | 1.426E-03 | AKR1B10, CYP1A1, CYP1B1, PPARD, TTR |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.205E-05 | 1.426E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0006091; generation of precursor metabolites and energy | 1.463E-05 | 1.642E-03 | CYP19A1, CYP1A2, GAA, GSK3B, NOX4, PKM, PPARD, XDH |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.483E-05 | 1.655E-03 | AR, ESR1, ESR2, NR1H4, PPARA, PPARD |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 1.706E-05 | 1.834E-03 | MAPK1, MAPT, PPARA, PTPN1, SYK, TP53 |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 1.884E-05 | 1.963E-03 | ADRA2A, CDC25B, ESR1, GSK3B, HIF1A, MAPK1, PTPN1, PTPN2, SYK, TP53 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.282E-05 | 2.279E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.433E-05 | 2.368E-03 | HIF1A, LMNA, PPARD, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.462E-05 | 2.379E-03 | AR, ESR1, ESR2, NR1H4, PPARA, PPARD |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 2.630E-05 | 2.490E-03 | ADRA2A, FLT3, MAPK1, NOX4, PLA2G1B, PTPN1, SYK |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.235E-05 | 2.860E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 3.235E-05 | 2.860E-03 | GPBAR1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 3.244E-05 | 2.860E-03 | ALOX15, GSK3B, HIF1A, HTT, MAPK1, MAPT, NOX4, TNKS, TNKS2, TP53 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 3.235E-05 | 2.860E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.235E-05 | 2.860E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 3.235E-05 | 2.860E-03 | ADRA2A, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 3.235E-05 | 2.860E-03 | GPBAR1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 4.004E-05 | 3.446E-03 | CDK6, CFTR, CYP1B1, MAPK1, NFKB1, PTGS2, TP53 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 4.116E-05 | 3.515E-03 | AR, ESR1, GSK3B, PPARA, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 4.421E-05 | 3.732E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.421E-05 | 3.732E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.860E-05 | 4.745E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032501; multicellular organismal process | GO:0006940; regulation of smooth muscle contraction | 6.376E-05 | 4.923E-03 | ADRA2A, ADRA2C, NMUR2, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 6.457E-05 | 4.923E-03 | NMUR2, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 6.457E-05 | 4.923E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 6.457E-05 | 4.923E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 6.457E-05 | 4.923E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 6.457E-05 | 4.923E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.457E-05 | 4.923E-03 | CYP1A1, CYP1A2 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 6.466E-05 | 4.923E-03 | GSK3B, NFKB1, PKM, PLA2G1B, TP53, TSHR |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 6.457E-05 | 4.923E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.457E-05 | 4.923E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 6.586E-05 | 4.997E-03 | CFTR, CYP19A1, CYP1B1, NPC1, PPARD |
| BP | GO:0009987; cellular process | GO:2001234; negative regulation of apoptotic signaling pathway | 6.999E-05 | 5.237E-03 | AR, HIF1A, HTT, LMNA, PTGS2, PTPN1 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 7.182E-05 | 5.319E-03 | NMUR2, PLA2G1B, PPARA, PPARD |
| MF | GO:0005488; binding | GO:0036094; small molecule binding | 7.403E-05 | 5.465E-03 | ABCC1, ABCG2, CDK6, CFTR, CSNK2A1, FLT3, GSK3B, HSD17B1, MAPK1, NMUR2, NOX4, NPC1, NR1H4, PKM, PLA2G1B, PPARD, RAB9A, SYK, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 7.574E-05 | 5.533E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 7.612E-05 | 5.533E-03 | HIF1A, NFKB1, PPARA, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 8.542E-05 | 6.078E-03 | CYP19A1, CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 8.528E-05 | 6.078E-03 | GSK3B, HIF1A, HTT, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 9.587E-05 | 6.778E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0009987; cellular process | GO:0010821; regulation of mitochondrion organization | 1.022E-04 | 7.154E-03 | GSK3B, HIF1A, HTT, LMNA, MAPT, TP53 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.071E-04 | 7.284E-03 | CYP19A1, CYP3A4, ESR1 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.071E-04 | 7.284E-03 | MAPT, PTPN1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.074E-04 | 7.284E-03 | CYP1A1, CYP3A4 |
| BP | GO:0002376; immune system process | GO:0002682; regulation of immune system process | 1.120E-04 | 7.574E-03 | ALOX15, CA2, CDK6, CYP19A1, ESR1, HIF1A, MAPK1, NFKB1, NR1H4, PLA2G1B, PTPN1, PTPN2, SYK, THPO, TP53 |
| BP | GO:0050896; response to stimulus | GO:0035774; positive regulation of insulin secretion involved in cellular response to glucose stimulus | 1.192E-04 | 7.962E-03 | CFTR, HIF1A, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.237E-04 | 8.237E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.301E-04 | 8.596E-03 | CSNK2A1, GSK3B, MAPK1, TNKS |
| BP | GO:0008152; metabolic process | GO:0072330; monocarboxylic acid biosynthetic process | 1.308E-04 | 8.596E-03 | ALOX15, CYP1A1, PKM, PLA2G1B, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0043255; regulation of carbohydrate biosynthetic process | 1.506E-04 | 9.672E-03 | GSK3B, NFKB1, PPARA, PTPN2 |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 1.579E-04 | 9.942E-03 | CYP1A1, PPARD, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.607E-04 | 9.942E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.607E-04 | 9.942E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0008013; beta-catenin binding | 1.579E-04 | 9.942E-03 | AR, CSNK2A1, ESR1, GSK3B |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.607E-04 | 9.942E-03 | CSNK2A1, HIF1A, MAPT |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.607E-04 | 9.942E-03 | CA1, CA2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.318E-19 | 1.465E-15 | CA1, CA12, CA14, CA2, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.734E-16 | 9.438E-13 | CA1, CA12, CA14, CA2, CA5A, CA5B, CA6, CA7, CA9, CFTR |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.660E-19 | 8.062E-17 | CA12; CA1; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.002E-08 | 2.596E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 4.944E-07 | 2.347E-05 | AR; GSK3B; CDK6; FLT3; MAPK1; PTGS2; HIF1A; TP53; NFKB1; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.426E-07 | 2.347E-05 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.372E-06 | 6.839E-05 | PKM; FLT3; MAPK1; TP53; HIF1A |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 4.064E-06 | 7.549E-05 | POLB; CDK6; PKM; SYK; MAPK1; TP53; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.394E-06 | 7.340E-05 | GSK3B; MAPK1; ESR1; NFKB1; ESR2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.631E-06 | 7.549E-05 | ABCC1; CDK6; CYP1B1; MAPK1; PTGS2; TP53; NFKB1; CDC25B |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.166E-06 | 7.340E-05 | CA2; NR1H4; CYP3A4; CFTR; ABCG2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.800E-06 | 7.549E-05 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; NFKB1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.132E-06 | 6.839E-05 | PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 9.658E-06 | 1.193E-04 | GSK3B; AR; MAPK1; TP53; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.459E-06 | 9.311E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 7.991E-06 | 1.063E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.316E-05 | 3.825E-04 | FLT3; MAPK1; NFKB1; PPARD |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.791E-05 | 4.099E-04 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.921E-05 | 6.026E-04 | CDK6; MAPK1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 6.713E-05 | 6.452E-04 | GSK3B; MAPK1; PPARA; TP53; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.260E-04 | 9.481E-04 | PLA2G1B; MAOA; GAA; ALOX15; PTGS2; CYP3A4; CYP19A1; PKM; AKR1B10; HSD17B1; CYP1A2; CYP1A1; XDH |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 8.794E-05 | 7.244E-04 | GSK3B; SYK; MAPK1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.794E-05 | 7.244E-04 | CDK6; MAPK1; TP53; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.794E-05 | 7.244E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.663E-04 | 1.199E-03 | CDK6; PTGS2; TP53; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.393E-04 | 2.712E-03 | MAPK1; PPARA; CFTR; NFKB1; TSHR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 4.703E-04 | 2.712E-03 | GSK3B; SYK; CSNK2A1; TP53; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.124E-04 | 2.643E-03 | PTPN1; GSK3B; PPARA; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.249E-04 | 1.556E-03 | SYK; CSNK2A1; PTGS2; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.571E-04 | 2.712E-03 | MAOA; ALOX15; MAPK1; PTGS2 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 7.672E-04 | 3.689E-03 | GSK3B; CDK6; SYK; MAPK1; TP53; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.932E-04 | 3.207E-03 | GSK3B; MAPK1; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.932E-04 | 3.207E-03 | ABCC1; MAPK1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.055E-03 | 4.682E-03 | LMNA; MAPK1; TP53; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 6.710E-04 | 3.414E-03 | GSK3B; CDK6; TP53; CDC25B |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.112E-03 | 4.811E-03 | GSK3B; CSNK2A1; TP53; PPARD |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.338E-03 | 5.262E-03 | MAPK1; MAPT; TP53; NFKB1; CDC25B |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.233E-03 | 4.960E-03 | CDK6; MAPK1; TP53; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 6.175E-04 | 3.237E-03 | GSK3B; MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 7.676E-04 | 3.689E-03 | CDK6; MAPK1; TP53 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 3.769E-04 | 2.508E-03 | ABCC1; CFTR; ABCG2 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.033E-03 | 4.682E-03 | GSK3B; MAPK1; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.071E-03 | 1.351E-02 | MAPK1; TP53; HIF1A; ESR1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.185E-03 | 4.881E-03 | CDK6; MAPK1; TP53 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.033E-03 | 4.682E-03 | PLA2G1B; ALOX15; PTGS2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.939E-03 | 1.336E-02 | MAPK1; ESR1; ESR2 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.530E-03 | 5.752E-03 | CDK6; MAPK1; TP53 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.185E-03 | 4.881E-03 | CYP1A2; CYP1A1; CYP3A4 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 9.385E-03 | 2.748E-02 | POLB; GSK3B; TP53; NFKB1 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 3.613E-03 | 1.276E-02 | CA2; PLA2G1B; CFTR |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 5.287E-03 | 1.633E-02 | MAPK1; PTGS2; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.401E-03 | 1.410E-02 | MAPK1; HIF1A; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.657E-03 | 6.099E-03 | MAPK1; PTGS2; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 4.522E-03 | 1.422E-02 | GSK3B; MAPK1; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.409E-03 | 5.415E-03 | MAOA; CYP1A2; CYP3A4 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.723E-03 | 6.210E-03 | PTPN1; CSNK2A1; MAPK1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 8.733E-03 | 2.605E-02 | SYK; MAPK1; NFKB1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.194E-02 | 3.228E-02 | NMUR2; ADRA2C; ADRA2A; TSHR |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.005E-02 | 2.850E-02 | PTPN1; GSK3B; MAPK1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.256E-02 | 3.343E-02 | GSK3B; PPARA; NFKB1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.642E-02 | 4.002E-02 | MAPK1; ADRA2C; ADRA2A |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.858E-02 | 4.343E-02 | GSK3B; MAPK1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.669E-02 | 4.009E-02 | GSK3B; MAPK1; MAPT |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.943E-02 | 4.422E-02 | SYK; MAPK1; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.000E-02 | 4.447E-02 | FLT3; TP53; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.148E-02 | 4.532E-02 | CSNK2A1; TP53; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.209E-02 | 4.605E-02 | GSK3B; MAPK1; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.584E-02 | 3.971E-02 | MAPK1; HIF1A |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.634E-02 | 4.002E-02 | MAPK1; PTGS2 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 2.005E-02 | 4.447E-02 | SYK; MAPK1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.389E-02 | 3.587E-02 | PTGS2; TSHR |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.896E-02 | 4.373E-02 | MAPK1; HIF1A |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 2.349E-02 | 4.837E-02 | CA2; CFTR |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 2.117E-02 | 4.522E-02 | PPARA; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.842E-02 | 4.343E-02 | MAPK1; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.408E-02 | 4.901E-02 | MAPK1; NFKB1 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.061E-02 | 4.457E-02 | PPARA; PPARD |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.437E-02 | 3.655E-02 | MAPK1; NFKB1 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 2.061E-02 | 4.457E-02 | CDK6; TP53 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.342E-02 | 3.519E-02 | GSK3B; TP53 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.034E-02 | 2.886E-02 | PKM; MAPK1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.076E-02 | 2.955E-02 | MAOA; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 7.628E-03 | 2.315E-02 | MAPK1; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 9.530E-03 | 2.748E-02 | CYP3A4; XDH |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.871E-03 | 1.336E-02 | MAPK1; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.139E-03 | 1.351E-02 | AKR1B10; GAA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.002E-04 | 7.878E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; SYK; TP53; CA9; MAPK1; FLT3; PKM |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; SYK; PTGS2; ADRA2C; PLA2G1B |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ADRA2C; ACHE |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PTGS2; PTGS2; PTGS2; PTGS2; ESR1; ADRA2C; ADRA2A; ACHE; PKM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK; PTGS2; PTGS2; PTGS2; PTGS2; PLA2G1B |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; MAOA |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD; ADRA2C |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2; MAOA |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; PLA2G1B; ABCC1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; HIF1A; SYK; TP53; CA1; PTGS2; CA9; MAPK1; NFKB1; FLT3; FLT3; ESR1; ESR1; ACHE; CDC25B; CSNK2A1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; PTGS2; NFKB1; PPARD |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; PTGS2; ABCC1; ABCC1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; CA9; FLT3; FLT3; ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; PTGS2; ADRA2C; MAOA; ACHE; ACHE; ACHE; MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK; PLA2G1B |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| NA: NA | GIST | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; PTGS2; PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; MAOA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1 |